Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Abstract C202: Discovery and initial characterization of the clinical compound ABT-348, a potent inhibitor of the VEGF, PDGF, and Aurora kinase families.

Michael L. Curtin, Robin Heyman, Robin R. Frey, Niru B. Soni, Patick A. Marcotte, Lori J. Pease, Keith B. Glaser, Terrance J. Magoc, Paul Tapang, Daniel H. Albert, Donald J. Osterling, Amanda M. Olson, Jennifer J. Bouska, Zhiwen Guan, Ruth L. Martin, Kent D. Stewart, Chris Tse, Steven K. Davidsen, Michael R. Michaelides

Mol Cancer Ther (2011) 10 (11_Supplement): C202.

https://doi.org/10.1158/1535-7163.TARG-11-C202

Published: 12 November 2011

View article titled, Abstract C202: Discovery and initial characterization of the clinical compound ABT-348, a potent inhibitor of the VEGF, PDGF, and Aurora kinase families.

Journal Articles

Abstract A239: Preclinical characterization of ABT-348, a kinase inhibitor targeting the Aurora, VEGFR/PDGFR, and SRC kinase families.

Mol Cancer Ther (2011) 10 (11_Supplement): A239.

https://doi.org/10.1158/1535-7163.TARG-11-A239

Published: 12 November 2011

View article titled, Abstract A239: Preclinical characterization of ABT-348, a kinase inhibitor targeting the Aurora, VEGFR/PDGFR, and SRC kinase families.

Journal Articles

The Multitargeted Receptor Tyrosine Kinase Inhibitor Linifanib (ABT-869) Induces Apoptosis through an Akt and Glycogen Synthase Kinase 3β–Dependent Pathway

Jenny E. Hernandez-Davies, Joan P. Zape, Elliot M. Landaw, Xiaolin Tan, Ajia Presnell, Diana Griffith, Michael C. Heinrich, Keith B. Glaser, Kathleen M. Sakamoto

Mol Cancer Ther (2011) 10 (6): 949–959.

https://doi.org/10.1158/1535-7163.MCT-10-0904

Published: 08 June 2011

View article titled, The Multitargeted Receptor Tyrosine Kinase Inhibitor Linifanib (ABT-869) Induces Apoptosis through an Akt and Glycogen Synthase Kinase 3β–Dependent Pathway

Includes: Supplementary data

Journal Articles

ABT-869 Inhibits the Proliferation of Ewing Sarcoma Cells and Suppresses Platelet-Derived Growth Factor Receptor β and c-KIT Signaling Pathways

Alan K. Ikeda, Dejah R. Judelson, Noah Federman, Keith B. Glaser, Elliot M. Landaw, Christopher T. Denny, Kathleen M. Sakamoto

Mol Cancer Ther (2010) 9 (3): 653–660.

https://doi.org/10.1158/1535-7163.MCT-09-0812

Published: 09 March 2010

View article titled, ABT-869 Inhibits the Proliferation of Ewing Sarcoma Cells and Suppresses Platelet-Derived Growth Factor Receptor β and c-KIT Signaling Pathways

Journal Articles

Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors

Jun Guo, Patrick A. Marcotte, J. Owen McCall, Yujia Dai, Lori J. Pease, Michael R. Michaelides, Steven K. Davidsen, Keith B. Glaser

Mol Cancer Ther (2006) 5 (4): 1007–1013.

https://doi.org/10.1158/1535-7163.MCT-05-0359

Published: 28 April 2006

View article titled, Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors

Journal Articles

Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor

Mol Cancer Ther (2006) 5 (4): 995–1006.

https://doi.org/10.1158/1535-7163.MCT-05-0410

Published: 28 April 2006

View article titled, Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor

Journal Articles

Gene Expression Profiling of Multiple Histone Deacetylase (HDAC) Inhibitors: Defining a Common Gene Set Produced by HDAC Inhibition in T24 and MDA Carcinoma Cell Lines

Keith B. Glaser, Michael J. Staver, Jeffrey F. Waring, Joshua Stender, Roger G. Ulrich, Steven K. Davidsen

Mol Cancer Ther (2003) 2 (2): 151–163.

Published: 01 February 2003

View article titled, Gene Expression Profiling of Multiple Histone Deacetylase (HDAC) Inhibitors: Defining a Common Gene Set Produced by HDAC Inhibition in T24 and MDA Carcinoma Cell Lines

Journal Articles

Transforming Growth Factor β Mimetics: Discovery of 7-[4-(4-Cyanophenyl) phenoxy]-Heptanohydroxamic Acid, a Biaryl Hydroxamate Inhibitor of Histone Deacetylase

Keith B. Glaser, Junling Li, Mary E. Aakre, Douglas W. Morgan, George Sheppard, Kent D. Stewart, Jennifer Pollock, Paul Lee, Chad Z. O’Connor, Steven N. Anderson, Donna J. Mussatto, Craig W. Wegner, Harold L. Moses

Mol Cancer Ther (2002) 1 (10): 759–768.

Published: 01 August 2002

View article titled, Transforming Growth Factor β Mimetics: Discovery of 7-[4-(4-Cyanophenyl) phenoxy]-Heptanohydroxamic Acid, a Biaryl Hydroxamate Inhibitor of Histone Deacetylase

NARROW

Abstract C202: Discovery and initial characterization of the clinical compound ABT-348, a potent inhibitor of the VEGF, PDGF, and Aurora kinase families.

Abstract A239: Preclinical characterization of ABT-348, a kinase inhibitor targeting the Aurora, VEGFR/PDGFR, and SRC kinase families.

The Multitargeted Receptor Tyrosine Kinase Inhibitor Linifanib (ABT-869) Induces Apoptosis through an Akt and Glycogen Synthase Kinase 3β–Dependent Pathway

ABT-869 Inhibits the Proliferation of Ewing Sarcoma Cells and Suppresses Platelet-Derived Growth Factor Receptor β and c-KIT Signaling Pathways

Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors

Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor

Gene Expression Profiling of Multiple Histone Deacetylase (HDAC) Inhibitors: Defining a Common Gene Set Produced by HDAC Inhibition in T24 and MDA Carcinoma Cell Lines

Transforming Growth Factor β Mimetics: Discovery of 7-[4-(4-Cyanophenyl) phenoxy]-Heptanohydroxamic Acid, a Biaryl Hydroxamate Inhibitor of Histone Deacetylase

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only